Alnylam is at the forefront of RNAi therapeutics with a robust pipeline of investigational medicines. Learn about Alnylam's pipeline of products in clinical development.

Feb 25, 2025 · Alnylam is on track to meet its ambitious “2-2-5” pipeline and platform expansion goal announced at R&D Day in 2023. This includes filing Investigational New Drug (IND) …

Oct 30, 2025 · Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development.

Our robust pipeline of investigational RNAi therapeutics is currently focused on several disease areas including transthyretin amyloidosis, rare diseases, cardiovascular diseases, metabolic …

Alnylam’s pipeline of investigational RNAi therapeutics is currently focused in four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Infectious …

Jun 9, 2025 · Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of …

Mar 23, 2025 · Programs Enhancing productivity and building capabilities with global partners 17 Robust and High-Value Pipeline of RNAi Therapeutics * Vutrisiran 1and fitusiran are under …

Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality, and is now advancing a robust pipeline of investigational RNAi therapeutics, with three …

Partnered, Alnylam-led development with US profit split and milestones/royalties ex-US

1 Out-licensed with milestones and/or royalties 2 Partnered, Alnylam-led development with US profit split and milestones/royalties ex-US 3 Partner-led with profit split 4 Product developed as …